Total item
Cart Subtotal
$0.00 Black Friday & Year End Sale starting Nov 21st 2022 through Jan 2nd 2023, enjoy 20% off sitewide
- Satoko Yamaoka, .et al. Development of accelerated high-throughput antiviral screening systems for emerging orthomyxoviruses, Antiviral Res, 2022, Apr;200:105291 PMID: 35296419
- Crystal A Mendoza, .et al. The NF- κB inhibitor, SC75741, is a novel antiviral against emerging tick-borne bandaviruses, Antiviral Res, 2021, Jan;185:104993 PMID: 33296695
- Liva Checkmahomed, .et al. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses, Viruses, 2020, Oct; 12(10): 1139 PMID: 33049959
- JE Comer, .et al. Filovirus Virulence in Interferon α,β and γ Double Knockout Mice, and Treatment with Favipiravir, Viruses, 2019, Feb 3;11(2). pii: E137 PMID: 30717492
- Ma J, .et al. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo, Antiviral Res, 2018, Feb;150:112-122 PMID: 29253498
- Ji-Ae Kim, .et al. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models, Viruses, 2018, Feb; 10(2): 72 PMID: 29425176
- Haejin Chun, .et al. Efficient antiviral co-delivery using polymersomes by controlling the surface density of cell-targeting groups for influenza A virus treatment, Polym Chem, 2018, 9: 2116-2123
- Baz M, .et al. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus, Viruses, 2018, Nov 3;10(11) PMID: 30400276
- Sehee Park, .et al. Combination Effects of Peramivir and Favipiravir against Oseltamivir-Resistant 2009 Pandemic Influenza A(H1N1) Infection in Mice, PLoS One., 2014, 9(7): e101325 PMID: 24992479
Biological Activity
T-705, a substituted pyrazine compound, has been found to exhibit potent anti-influenza virus activity in vitro and in vivo.
Targets
| RNA-dependent RNA polymerase | ||||
| In vitro | DMSO | 29 mg/mL (184.59 mM) | |
| Water | Warmed: 5 mg/mL (31.82 mM) | ||
| Ethanol | Warmed: 21 mg/mL (133.67 mM) | ||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 63.65 mL | 318.27 mL | 636.54 mL |
| 0.5 mM | 12.73 mL | 63.65 mL | 127.31 mL |
| 1 mM | 6.37 mL | 31.83 mL | 63.65 mL |
| 5 mM | 1.27 mL | 6.37 mL | 12.73 mL |
*The above data is based on the productmolecular weight 157.1. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Catalog Num | A11590 |
|---|---|
| Actions | Inhibitor |
| CAS No. | 259793-96-9 |
| Formula | C5H4FN3O2 |
| M. Wt | 157.1 |
| Purity | >98% |
| Synonyms | T705, T 705 |
| SMILES | C1=C(N=C(C(=O)N1)C(=O)N)F |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
Keywords:buy T-705 (Favipiravir) | T-705 (Favipiravir) Supplier | purchase | cost | manufacturer | order | distributor | buy 259793-96-9| 259793-96-9 Supplier | purchase 259793-96-9 | 259793-96-9 cost | 259793-96-9 manufacturer | order 259793-96-9 | 259793-96-9 distributor
Adooq Quality Guarantee
We promise all products perform as described.